You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

Focal Tumour Ablation: Early-stage Primary Lung Cancer and Lung Metastases

ID: FA4 Aug 2016
Type of Content: Guidelines & Advice, Evidence Summary
Document Status: Current
Authors:
J. Kachura, F. Baldassarre, S. Athreya, M. Midia, R. Malthaner, The Interventional Oncology Steering Committee

Guideline Objective

To provide a systematic literature review that will be one of the six components of the Recommendation Report of the Interventional Oncology Steering Committee (other components will include demand forecasting, costing analysis, jurisdictional review, system capacity, literature review, and current state, summary available at www.cancercare.on.ca/fta.)

Patient Population

Patients with early-stage, primary lung cancer or lung metastases.

Intended Guideline Users

Clinicians (radiologists, thoracic surgeons, medical and radiation oncologists, and respirologists) involved in the delivery of focal tumour ablation for lung cancer patients.

Research Question(s)

These research questions were developed to direct the search for available evidence on focal tumour ablation for early-stage primary lung cancer and lung metastases:

  1. What is the effectiveness of focal tumour ablation for the treatment of patients with early-stage primary lung cancer or lung metastases?
  2. What are the complications associated with focal tumour ablation for early-stage primary lung cancer or lung metastases?
  3. What patient populations are most likely to benefit from focal tumour ablation for early-stage primary lung cancer or lung metastases?